Laidlaw & Company, which underwrote the recent IPO for Therapix Biosciences (NASDAQ: TRPX), has initiated research coverage of the company, giving it a “Buy” rating and suggesting a price target of $18. Analyst Francois Brisebois sees the company’s THX-TS01, which combines synthetic THC with PEA, as the source of most of the value in the company, valuing it at $11.75 per share based on potential U.S. sales and EU royalties. THX-TS01 addresses the symptoms of Tourette Syndrome. He also credits the shares $1.75 for its THX-ULD01, which addresses  mild cognitive impairment. The remainder of the value is in cash of $4.50 per share projected for year-end 2018. In the 31-page report, Brisebois also suggests the company could be a potential acquisition target given what he calls a “de-risked profile” due to the repurposing of a previously approved drug, dronabinol.

Download Laidlaw & Company Therapix Research Report

Last week, the company provided an update that indicated it will be presenting at several conferences:

The 7th Annual LD Micro Invitational:

The 2017 Marcum MicroCap Conference:

The 27th Annual ICRS Symposium on the Cannabinoids:

Exclusive article by Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email